ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 20193007]

NRG-GY012: A randomized Phase II study comparing single-agent Olaparib, Single Agent Cediranib, and the combination of Cediranib /Olaparib in women with Recurrent, persistent or Metastatic Endometrial Cancer

Testing the combination of olaparib and cediranib in comparison to cediranib alone, and olaparib alone in recurrent endometrial cancer.

The purpose of this study is to compare any good and bad effects of using experimental study drugs cediranib alone, olaparib alone, or a combination of cediranib and olaparib. This study will allow the researchers to know whether one of these approaches is better, the same, or worse than the usual approach.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3071